Citations 1
623 Final results from phase 1, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
Geva, Ravit , Golan, Talia , Cohen, Jonathan , Zhaohui, Jin, LoRusso, Patricia , Friedman, Itay, Hakim, Motti, Ziv, Dana Haves, Hashmueli, Sharon, Mandel, Ilana , Moshe, Tehila Ben, Crawford, Nigel P.S., Abbadessa, Giovanni , Wu, Meijing, Perets, Ruth , Stemmer, Salomon M. , Fakih, Marwan , Lieu, Christopher H. , Zhaohui, Jin, Crawford, Nigel, Perez, Raymond P. , Borad, Mitesh J.
Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A717-A717
